RESUMEN
Herein, we report a unique case of generalized eruptive keratoacanthoma (GEKA) in a 47-year-old Chinese man presenting with extensive pruritic papules and nodules accompanied by oral lesions. He also had a 2-year history of vitiligo and long-term experience of working outdoors. Biopsies were consistent with keratoacanthoma . Interestingly, prurigo nodularis (PN) was found in histopathology at 1-year follow up. To our knowledge, this is the first report describing a case of GEKA with oral lesions complicated with vitiligo and developed with PN.
Asunto(s)
Queratoacantoma/complicaciones , Prurigo/complicaciones , Vitíligo/etiología , Antialérgicos/uso terapéutico , Biopsia , Humanos , Queratoacantoma/diagnóstico , Queratoacantoma/tratamiento farmacológico , Queratoacantoma/patología , Queratolíticos/uso terapéutico , Masculino , Persona de Mediana Edad , Mucosa Bucal/patología , Extractos Vegetales/uso terapéutico , Prurigo/diagnóstico , Prurigo/tratamiento farmacológico , Prurigo/patología , Piel/patología , Resultado del Tratamiento , Tripterygium/química , Vitíligo/diagnóstico , Vitíligo/patologíaRESUMEN
BACKGROUND: Protein kinases (PKs) are indispensable for most cellular processes, and deregulation of PKs can lead to activation of oncogenic and anti-apoptotic pathways and immune dysregulation. OBJECTIVE: To report the development of keratoacanthoma (KA)-type squamous cell carcinomas (SCCs) in patients treated with the multikinase inhibitor sorafenib for the treatment of solid tumors, to present the possible mechanisms for induction of these SCCs, and to discuss the implications for discontinuation of therapy and possible cotherapies to decrease this side effect. PARTICIPANTS: Fifteen patients taking the multikinase inhibitor sorafenib for the treatment of solid tumors who developed multiple KA-type SCCs, which continued to develop while the patients were undergoing therapy but stopped with discontinuation of sorafenib. LIMITATIONS: This report is limited because it is a retrospective study that included only patients who developed multiple KA-type SCCs. CONCLUSIONS: Development of cutaneous SCCs appears to be a side effect limited to sorafenib, a multikinase inhibitor that inhibits not only multiple tyrosine kinases (TKs), but also the serine-threonine kinase Raf. The incidence of cutaneous SCCs does not appear greater with multikinase inhibitors that inhibit only TKs.
Asunto(s)
Antineoplásicos/efectos adversos , Bencenosulfonatos/efectos adversos , Carcinoma de Células Escamosas/inducido químicamente , Queratoacantoma/inducido químicamente , Neoplasias Primarias Secundarias/inducido químicamente , Inhibidores de Proteínas Quinasas/efectos adversos , Piridinas/efectos adversos , Neoplasias Cutáneas/inducido químicamente , Adulto , Antineoplásicos/uso terapéutico , Bencenosulfonatos/uso terapéutico , Carcinoma de Células Escamosas/patología , Femenino , Humanos , Queratoacantoma/patología , Masculino , Persona de Mediana Edad , Niacinamida/análogos & derivados , Compuestos de Fenilurea , Inhibidores de Proteínas Quinasas/uso terapéutico , Piridinas/uso terapéutico , Neoplasias Cutáneas/patología , SorafenibAsunto(s)
Anticarcinógenos/administración & dosificación , Antineoplásicos/efectos adversos , Bencenosulfonatos/efectos adversos , Queratoacantoma/prevención & control , Piridinas/efectos adversos , Enfermedades de la Piel/prevención & control , Tetrahidronaftalenos/administración & dosificación , Adenocarcinoma Papilar/tratamiento farmacológico , Anticarcinógenos/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Bencenosulfonatos/administración & dosificación , Bexaroteno , Carboplatino/administración & dosificación , Ensayos Clínicos como Asunto , Cistadenocarcinoma Seroso/tratamiento farmacológico , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Hipertrigliceridemia/inducido químicamente , Hipotiroidismo/inducido químicamente , Queratoacantoma/inducido químicamente , Queratoacantoma/patología , Persona de Mediana Edad , Recurrencia Local de Neoplasia/tratamiento farmacológico , Niacinamida/análogos & derivados , Neoplasias Ováricas/tratamiento farmacológico , Paclitaxel/administración & dosificación , Compuestos de Fenilurea , Piridinas/administración & dosificación , Enfermedades de la Piel/inducido químicamente , Enfermedades de la Piel/patología , Sorafenib , Tetrahidronaftalenos/efectos adversosRESUMEN
The annual incidence of all forms of skin cancer, the most common of all human cancers, is increasing yearly. A unique nutrient mixture (NM) was shown to exhibit anticancer activity in vivo and in vitro. We examined the effect of NM on the development of skin cancer induced by 7,12-dimethylbezanthracene (DMBA) in female SENCAR mice by a complete carcinogenesis protocol. Mice (n=55) were divided into four groups and carefully shaved on dorsum. After 2 days, the mice in Groups 1 (n=10), 3 (n=20), and 4 (n=20) were treated topically with 100 nM DMBA in 0.2 ml of acetone twice a week for 4 weeks; Group 2 (n=5), the control group, was treated with acetone 0.2 ml. Groups 1 and 2 were fed the regular diet. Group 3A (n=10) was fed a diet containing 0.5% NM from the day of DMBA treatment and 3B (n=10) the regular diet and received NM (75 mg in 0.4 ml of 1:1 acetone/water) topically to the shaved area 15 min before DMBA application twice a week for 4 weeks. Group 4 mice were fed a diet containing 0.5% NM for 2 weeks prior to the application of DMBA and then divided into two groups: 4A (n=10) was fed the 0.5% NM diet as in 3A, and 4B (n=10) the regular diet as described for 3B. Body weight and diet consumption of the mice were monitored and the skin tumors (papillomas) were counted and recorded. Ten weeks thereafter the mice were euthanized, skinned, and tumors were processed for histology. NM significantly (P<0.0001) inhibited DMBA-induced skin tumor multiplicity by 59, 62, 69, and 86% in NM-treated Groups 3A, 3B, 4A, and 4B, respectively. These results suggest that NM has strong potential as a useful therapeutic regimen for skin cancer by significantly inhibiting the incidence and tumor multiplicity of DMBA-induced skin tumors.
Asunto(s)
Aminoácidos/administración & dosificación , Dieta , Extractos Vegetales/administración & dosificación , Neoplasias Cutáneas/prevención & control , 9,10-Dimetil-1,2-benzantraceno , Acetilcisteína/administración & dosificación , Acetilcisteína/farmacología , Animales , Arginina/administración & dosificación , Ácido Ascórbico/administración & dosificación , Camellia sinensis , Carcinógenos , Cobre/administración & dosificación , Femenino , Queratoacantoma/patología , Queratoacantoma/prevención & control , Lisina/administración & dosificación , Manganeso/administración & dosificación , Ratones , Ratones Endogámicos SENCAR , Papiloma/patología , Papiloma/prevención & control , Prolina/administración & dosificación , Selenio/administración & dosificación , Piel/patología , Neoplasias Cutáneas/inducido químicamenteRESUMEN
The treatment of vitiligo is still a challenge. Among various therapeutic modalities, phototherapy with UVB narrowband (UVB-NB) is presently considered a treatment of choice for this skin disease. The exact skin cancer risk deriving from UVB-NB is a serious concern to be determined. We report a case of keratoacanthoma developed in the vitiligo area during a prolonged course of UVB-NB therapy.
Asunto(s)
Queratoacantoma/radioterapia , Terapia Ultravioleta/efectos adversos , Vitíligo/radioterapia , Edad de Inicio , Estudios de Seguimiento , Humanos , Queratoacantoma/diagnóstico , Queratoacantoma/patología , Masculino , Persona de Mediana Edad , Factores de Tiempo , Resultado del Tratamiento , Terapia Ultravioleta/métodos , Vitíligo/patología , Vitíligo/cirugíaRESUMEN
LEARNING OBJECTIVES: After studying this article, the participant should be able to: 1. Identify the subtypes of squamous cell carcinoma of the skin. 2. Identify factors that affect recurrence and/or metastasis. 3. Develop a surgical management plan for treating high-risk squamous cell carcinoma of the skin. In treating squamous cell carcinoma of the skin, a key concept in proper management is understanding why certain tumors are more prone to both recurrence and metastasis. When developing a surgical management plan, an understanding of "high risk" is essential. This article concentrates on identifying those tumor subtypes and factors that may serve as predictors of high-risk status as well as on providing management suggestions.
Asunto(s)
Carcinoma de Células Escamosas , Neoplasias Cutáneas , Enfermedad de Bowen/patología , Carcinoma Adenoescamoso/patología , Carcinoma de Células Escamosas/clasificación , Carcinoma de Células Escamosas/diagnóstico , Carcinoma de Células Escamosas/etiología , Carcinoma de Células Escamosas/radioterapia , Carcinoma de Células Escamosas/cirugía , Carcinoma Verrugoso/patología , Diferenciación Celular , Cicatriz/complicaciones , Crioterapia , Legrado , Terapia por Estimulación Eléctrica , Femenino , Predisposición Genética a la Enfermedad , Humanos , Incidencia , Queratoacantoma/diagnóstico , Queratoacantoma/patología , Masculino , Cirugía de Mohs , Invasividad Neoplásica , Neoplasias Inducidas por Radiación/etiología , Neoplasias Inducidas por Radiación/patología , Enfermedades de la Piel/diagnóstico , Enfermedades de la Piel/patología , Neoplasias Cutáneas/clasificación , Neoplasias Cutáneas/diagnóstico , Neoplasias Cutáneas/etiología , Neoplasias Cutáneas/radioterapia , Neoplasias Cutáneas/cirugía , Rayos Ultravioleta/efectos adversosRESUMEN
We describe a patient with generalized eruptive keratoacanthoma (KA) of Grzybowski showing the characteristic features of this extremely rare condition. Since the first description by Grzybowski in 1950, only 28 additional cases (including the present one) have been reported. This variety of KA most commonly affects patients during the fifth to seventh decade of life and appears as a generalized eruption of hundreds to thousands of follicular papules. The small pruriginous papules often have a keratotic centre and show microscopic features of KA. Marked facial involvement is characteristic and can lead to masked facies with ectropion, as in our patient. The course of the disease is chronic and the response to therapy is poor.
Asunto(s)
Facies , Queratoacantoma/patología , Enfermedades Cutáneas Papuloescamosas/patología , Acitretina/uso terapéutico , Fármacos Dermatológicos/uso terapéutico , Humanos , Interferón alfa-2 , Interferón-alfa/uso terapéutico , Queratoacantoma/tratamiento farmacológico , Masculino , Metotrexato/uso terapéutico , Persona de Mediana Edad , Terapia PUVA/métodos , Proteínas Recombinantes , Enfermedades Cutáneas Papuloescamosas/tratamiento farmacológico , Insuficiencia del TratamientoRESUMEN
Treatment of SKH-1 mice with ultraviolet B light (UV-B, 30 mJ/cm2) twice a week for 22-23 weeks resulted in tumor-free animals with a high risk of developing malignant and nonmalignant tumors during the next several months in the absence of further UV-B treatment (high-risk mice). In three separate experiments, oral administration of green tea or black tea (4-6 mg tea solids/ml) as the sole source of drinking fluid for 18-23 weeks to these high-risk mice inhibited the formation and decreased the size of nonmalignant squamous cell papillomas and keratoacanthomas as well as the formation and size of malignant squamous cell carcinomas. In one experiment all these inhibitory effects of tea were statistically significant, whereas in the two other experiments many but not all of the inhibitory effects of tea were statistically significant. The decaffeinated teas were inactive or less effective inhibitors of tumor formation than the regular teas, and adding caffeine back to the decaffeinated teas restored biological activity. Oral administration of caffeine alone (0.44 mg/ml) as the sole source of drinking fluid for 18-23 weeks inhibited the formation of nonmalignant and malignant tumors, and this treatment also decreased tumor size in these high-risk mice.
Asunto(s)
Anticarcinógenos/farmacología , Cafeína/farmacología , Carcinoma de Células Escamosas/prevención & control , Queratoacantoma/prevención & control , Neoplasias Inducidas por Radiación/prevención & control , Papiloma/prevención & control , Neoplasias Cutáneas/prevención & control , Té , Administración Oral , Animales , Anticarcinógenos/administración & dosificación , Cafeína/administración & dosificación , Carcinoma de Células Escamosas/patología , Femenino , Queratoacantoma/patología , Ratones , Ratones Pelados , Neoplasias Inducidas por Radiación/patología , Papiloma/patología , Neoplasias Cutáneas/patología , Rayos Ultravioleta/efectos adversosRESUMEN
BACKGROUND: Keratoacanthoma is a common cutaneous neoplasm, although the persistent form is less common and often more difficult to manage. Multiple treatment approaches have been attempted with variable efficacy. Establishing the diagnosis and selecting a treatment plan for persistent keratoacanthoma is often challenging. OBJECTIVE: Our purpose is to describe the difficulty one may encounter in the diagnosis and treatment of persistent keratoacanthoma. Hopefully, review of this clinical conundrum may facilitate the management of the reader's future patients. METHODS: We describe a case of persistent keratoacanthoma where the diagnosis was initially elusive and the management challenging. Our thought process during each stage of diagnosis and management is described in the form of "issues" with references to the appropriate literature. RESULTS: After several diagnostic and therapeutic interventions, successful treatment was achieved with administration of oral isotretinoin. Long-term remission continued as the dosage was tapered. CONCLUSION: Persistent keratoacanthoma may be challenging to diagnose and manage, presenting a clinical conundrum. Careful review of the clinicopathologic presentation and an understanding of the various treatment options may result in a successful outcome.
Asunto(s)
Queratoacantoma/cirugía , Recurrencia Local de Neoplasia/cirugía , Neoplasias Cutáneas/cirugía , Administración Oral , Quimioterapia Adyuvante , Terapia Combinada , Procedimientos Quirúrgicos Dermatologicos , Humanos , Isotretinoína/administración & dosificación , Queratoacantoma/diagnóstico , Queratoacantoma/tratamiento farmacológico , Queratoacantoma/patología , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia/diagnóstico , Recurrencia Local de Neoplasia/tratamiento farmacológico , Recurrencia Local de Neoplasia/patología , Neoplasias Primarias Múltiples/diagnóstico , Neoplasias Primarias Múltiples/tratamiento farmacológico , Neoplasias Primarias Múltiples/patología , Neoplasias Primarias Múltiples/cirugía , Piel/patología , Neoplasias Cutáneas/diagnóstico , Neoplasias Cutáneas/tratamiento farmacológico , Neoplasias Cutáneas/patología , Resultado del TratamientoRESUMEN
We report the results of a long-term (12.8 years) follow-up study of the detection of malignant and benign skin tumours in patients with psoriasis, who were treated with PUVA according to the European, 'high single-dose' regimen. A total of 13 squamous cell carcinomas (SCC) and 24 basal cell carcinomas (BCC) were diagnosed in 11 of 260 patients. The incidence of both SCC and BCC was increased in comparison with the general Dutch population. The ratio of SCC to BCC in the general population was 1:8 but was 1:2.5 in our study group. A positive correlation was observed between the development of SCC and the total UVA dosage, the age of the patient at the start of the PUVA treatment and a history of arsenic use. This dose-related increase in the incidence of SCC, reported in studies from the U.S.A., has not been found in earlier European studies. The average time period between the start of PUVA therapy and the diagnosis of the first malignant skin tumour was 6.0 years for SCC and 4.7 years for BCC. Among the 49 benign skin tumours were actinic keratoses, a keratoacanthoma and 'PUVA keratoses', a newly described hyperkeratotic lesion, especially found in PUVA-treated patients.
Asunto(s)
Carcinoma Basocelular/inducido químicamente , Carcinoma de Células Escamosas/inducido químicamente , Terapia PUVA/efectos adversos , Neoplasias Cutáneas/inducido químicamente , Factores de Edad , Anciano , Anciano de 80 o más Años , Carcinoma Basocelular/epidemiología , Carcinoma de Células Escamosas/epidemiología , Femenino , Estudios de Seguimiento , Humanos , Incidencia , Queratoacantoma/inducido químicamente , Queratoacantoma/patología , Masculino , Persona de Mediana Edad , Terapia PUVA/métodos , Psoriasis/tratamiento farmacológico , Piel/patología , Neoplasias Cutáneas/epidemiologíaAsunto(s)
Carcinoma de Células Escamosas/etiología , Queratoacantoma/patología , Terapia PUVA/efectos adversos , Enfermedades de la Piel/tratamiento farmacológico , Neoplasias Cutáneas/etiología , Anciano , Carcinoma de Células Escamosas/patología , Humanos , Masculino , Piel/patología , Neoplasias Cutáneas/patologíaRESUMEN
The carcinogenic effect of treatment with heavy catalytic gasoil on the skin of 120 albino noninbred mice was studied. Skin tumors arose in 97 of 115 animals (84.3%) which survived until the appearance of the first papillomas. In 21 mice, tumors were benign while cancer developed in 76 animals. 116 visceral neoplasms were detected in 99 animals (93.4%). They were found in the upper part of digestive tract of 57, the hematopoietic and lymphatic tissues of 57 and in the lungs of two animals. The study established a high carcinogenicity of heavy catalytic gasoil matched by early appearance and multicentric growth of tumors as well as rapid generalization of the process.
Asunto(s)
Aceites Combustibles/toxicidad , Neoplasias Primarias Múltiples/inducido químicamente , Petróleo/toxicidad , Lesiones Precancerosas/inducido químicamente , Neoplasias Cutáneas/inducido químicamente , Animales , Carcinoma de Células Escamosas/inducido químicamente , Carcinoma de Células Escamosas/patología , Queratoacantoma/inducido químicamente , Queratoacantoma/patología , Ratones , Neoplasias Primarias Múltiples/patología , Papiloma/inducido químicamente , Papiloma/patología , Lesiones Precancerosas/patología , Neoplasias Cutáneas/patologíaRESUMEN
We report two patients who developed multiple keratoacanthomas while receiving photochemotherapy (PUVA). Both patients had received excessive doses of PUVA, which resulted in severe phototoxicity. The role of PUVA in the production of these lesions is discussed.